Treatment with Long-Acting Somatostatin Analogues in Patients with Acromegaly: When and How

Luigi Simone Aversa; Michela Sibilla; Nunzia Prencipe; Valentina Gasco; Ezio Ghigo; Silvia Grottoli

doi:10.1159/000539990

Treatment with Long-Acting Somatostatin Analogues in Patients with Acromegaly: When and How

Front Horm Res. 2024:55:182-200. doi: 10.1159/000539990.

Authors

Luigi Simone Aversa¹, Michela Sibilla², Nunzia Prencipe², Valentina Gasco², Ezio Ghigo², Silvia Grottoli²

Affiliations

¹ Division of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy, [email protected].
² Division of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.

PMID: 39586277
DOI: 10.1159/000539990

Abstract

Somatostatin and its analogs have been for years a mainstay treatment for a variety of hypersecretory conditions and neoplasms of the endocrine system. This chapter summarizes their pharmacological properties, their indication in the context of acromegaly, and the best way to handle this class of drugs for the treatment of the patient with acromegaly.

Publication types

Review

MeSH terms

Acromegaly* / drug therapy
Human Growth Hormone / administration & dosage
Human Growth Hormone / therapeutic use
Humans
Octreotide / administration & dosage
Octreotide / therapeutic use
Somatostatin* / analogs & derivatives
Somatostatin* / therapeutic use

Substances

Somatostatin
Human Growth Hormone
Octreotide